Artificial intelligence and psychedelic medicine
Annals of the New York Academy of Sciences September 23, 2024 Jerome Sarris, Andreas Halman, Anna Urokohara et al. 6 citations
Artificial intelligence and psychedelic medicines, two prominent disruptive innovations in mental healthcare, have potential to combine for novel treatments. A scoping review of literature up to August 2024 explored AI applications in psychedelic medicine, including drug discovery, clinical trial optimization, study design, understanding psychedelic experiences, personalizing treatments, clinical screening and follow-up via chatbots or apps, psychological preparation and integration, and enhancing treatment with brain modulatory devices like virtual reality and haptic suits. Challenges include data protection and ethical safeguards. Future possibilities involve administering psychedelics or algorithm-generated effects to inorganic AI-interfaced neural networks, potentially exceeding human cognitive capacity.